Approval of sotorasib with panitumumab was based on findings from the randomized, open-label, controlled CodeBreaK 300 trial showing improved overall response rates (ORR) and progression-free ...

MADRID — Sotorasib plus panitumumab prolonged PFS compared with standard of care for patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer, study results presented at ESMO ...

Vectibix ® in combination with sotorasib, is indicated for the treatment of adult patients with KRAS G12C-mutated mCRC, as determined by an FDA-approved test, who have received prior treatment ...

The median PFS at a lower sotorasib dose of 240 mg plus panitumumab was 3.9 months (HR 0.58, 95% CI 0.36-0.93, P =0.03), according to the study, which was also published in the New England Journal ...

Median duration of response was 4.4 months in the sotorasib 960 group and not reached in in the sotorasib 240 mg group. “Sotorasib plus panitumumab has an acceptable safety profile,” Fakih said.

THOUSAND OAKS, Calif., Oct. 22, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced data from the global Phase 3 CodeBreaK 300 trial evaluating two doses of LUMAKRAS ® (sotorasib) (960 mg or ...

Patients in Group 2 will receive sotorasib only. Those who have previously received a KRAS G12C inhibitor drug will be assigned to Group 3 and receive sotorasib and panitumumab.

The most common adverse reactions (≥ 20%) in patients receiving Vectibix ® in combination with sotorasib 960 mg were rash, dry skin, diarrhea, stomatitis, fatigue and musculoskeletal pain.

"With these new data, sotorasib plus panitumumab showed consistent efficacy across key subgroups at both doses and supports the biologic rationale of combining these two biomarker-directed ...